biostudies-literatureUnknown28(5)Heckl SM<h4>Background</h4>Since the FLOT4 gastric cancer (GC) trial, the use of adjuvant chemotherapy has been perceived as limited and its added value questioned. We wanted to objectify this perception and reassess the value of adjuvant chemotherapy in a real-world setting.<h4>Methods</h4>In our retrospective cohort study we analyzed real-world data from 147 patients with GC or cancer of the gastroesophageal junction (AEG) who received perioperative FLOT. Data originated from clinical care at the university hospital, local hospitals and medical practices. Clinicopathologic data, survival outcomes, and targetable biomarkers were analyzed.<h4>Results</h4>Median overall survival (OS) and tumor specific survival (TSS) were 19.4 ± 2.9 and 19.9 ± 3.1 months, respectively. 84.4% completed all cycles ofGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association982-992https://www.ebi.ac.uk/biostudies/studies/S-EPMC12378129biostudies-literatureImpact of adjuvant therapy on outcomes of cancer of the stomach and gastroesophageal junction in the real-world.PMC12378129Richter FEbert UBehrens HMRocken CUlase DBecker THeckl SMLetsch AfalseImpact of adjuvant therapy on outcomes of cancer of the stomach and gastroesophageal junction in the real-world.<h4>Background</h4>Since the FLOT4 gastric cancer (GC) trial, the use of adjuvant chemotherapy has been perceived as limited and its added value questioned. We wanted to objectify this perception and reassess the value of adjuvant chemotherapy in a real-world setting.<h4>Methods</h4>In our retrospective cohort study we analyzed real-world data from 147 patients with GC or cancer of the gastroesophageal junction (AEG) who received perioperative FLOT. Data originated from clinical care at the university hospital, local hospitals and medical practices. Clinicopathologic data, survival outcomes, and targetable biomarkers were analyzed.<h4>Results</h4>Median overall survival (OS) and tumor specific survival (TSS) were 19.4 ± 2.9 and 19.9 ± 3.1 months, respectively. 84.4% completed all cycles of2025-01-01T00:00:00Z2025 Sep2026-05-09T18:01:55.008Z2026-04-08T01:07:52.116ZS-EPMC123781294037990110.1007/s10120-025-01624-8